REGULATORY

Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi

By Tatsuya Otsuka June 6, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan should remove all barriers hampering domestic pharma companies from expanding overseas if it is to bolster their global competitiveness, and annual drug price revisions “should absolutely be discontinued,” Liberal Democratic Party (LDP) lawmaker Hanako Jimi tells Jiho. Dr Jimi…

To read the full story

All 10 Pharma-Backed Candidates Grab Upper House Seats
July 12, 2022
Pharma-Backed Upper House Candidates Kick Off Campaigning for July 10 Poll
June 23, 2022

REGULATORY

LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…